RPRX
Royalty Pharma plc
NASDAQ · USHealthcareBiotechnology
$57.30-1.52%
Price as of Jul 20, 2026
RPRX profitability
Royalty Pharma plc profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 100.0%
- EBITDA margin
- 69.6%
- EBIT margin
- 67.9%
- Net margin
- 33.9%
- Free cash flow margin
- 108.8%
Returns
- Return on equity
- 12.0%
- Return on assets
- 4.2%
- Return on invested capital
- 10.5%
- Asset turnover
- 0.12x
Cash efficiency
- Cash from operations
- $2.7B
- Cash per share
- $1.37
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.